Frontiers in Pharmacology | Pharmacogenetics and Pharmacogenomics

Mini Review

Published on 19 Dec 2025

Transcriptional rewiring in cancer driven by POLR2A/RPB1: mechanistic insights, non-coding RNA crosstalk, and therapeutic opportunities

in Pharmacogenetics and Pharmacogenomics

Adrian Szczepaniak
Kinga Jaskuła
Marta Zielińska
Jakub Godlewski

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1745087

199 views

Review

Accepted on 02 Dec 2025

Combining Exercise and Nanoparticle-Based Therapies: A Review of Physiological Synergies and Pharmacological Potential

in Pharmacogenetics and Pharmacogenomics

Lijuan Xiang
Zhanguo Su

Frontiers in Pharmacology

Methods

Published on 02 Dec 2025

StarTRAC-CYP2D6: a method for CYP2D6 allele-specific copy number determination using digital PCR

in Pharmacogenetics and Pharmacogenomics

Wendy Y. Wang
Erin C. Boone
Lancy Lin
David Joun
Andrea Gaedigk

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1715830

781 views

Original Research

Published on 27 Nov 2025

Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis

in Pharmacogenetics and Pharmacogenomics

Zhi-Hu Zhao
Tao Ling
Songqing Ye
Wei Luo
Jian-Xiong Ma
Xinlong Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1566890

635 views

Original Research

Published on 25 Nov 2025

Pharmacogenetic variations and clinical implications of actionable CYP2D6/CYP2C19 variants in Central Indian patients with common mental disorders

in Pharmacogenetics and Pharmacogenomics

Santenna Chenchula
Atal Shubham
Rozatkar Abhijit
Tamonud Modak
Kohat Komal
Ratinder Jhaj
Singh Jitendra
Satyaprakash V.
Sadasivam Balakrishnan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1697866

1,009 views

Original Research

Published on 21 Nov 2025

Assessing the views and opinions of psychiatric patients receiving genome-guided treatment within the scope of the PREPARE preemptive pharmacogenomics clinical study

in Pharmacogenetics and Pharmacogenomics

Margarita-Ioanna Koufaki
Maria-Theodora Pandi
Maria Skokou
Kariofyllis Karamperis
Konstantinos Vasileiou
Christina Mitropoulou
Marc S. Williams
George P. Patrinos

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1722339

476 views

Systematic Review

Published on 21 Nov 2025

Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis

in Pharmacogenetics and Pharmacogenomics

Shaban Mohammed
Zainab Ali
Nermin Mohammed
Ayman El-Menyar
Jassim Al Suwaidi
Moza Al-Hail
Wadha Al-Muftah
Rania Abdel-Latif
Maw Shin Sim

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1621327

948 views

Original Research

Published on 19 Nov 2025

Pharmacogenetic associations of CYP2D6 and CYP2C19 variants with anticholinergic drug burden and hyposalivation

in Pharmacogenetics and Pharmacogenomics

Olga A. Korczeniewska
Scott Diehl
Abdul Basir Barmak
Tong Tong Wu
Eli Eliav
Szilvia Arany

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1713345

478 views

Mini Review

Published on 13 Nov 2025

Inhibition of mesenchymal drift as a strategy for rejuvenation

in Pharmacogenetics and Pharmacogenomics

Lucas Paulo de Lima Camillo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1715559

1,513 views

Original Research

Published on 30 Oct 2025

Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder

in Pharmacogenetics and Pharmacogenomics

Daniel Hain
Andria L. Del Tredici
Ryan B. Griggs
Rebecca Law
Brent Mabey
Holly L. Johnson
Katherine Johansen Taber
Kevin G. Lynch
Alexander Gutin
David W. Oslin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1658616

2,066 views

Review

Published on 30 Oct 2025

Epigenetic pharmacology in aging: from mechanisms to therapies for age-related disorders

in Pharmacogenetics and Pharmacogenomics

Haikuan Yu
Taojin Feng
Chengcheng Zhang
Zhouguang Jiao
Wenkai Fan
Rongxian Jiang
Dewen Kong
Fubing Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1699296

2,623 views

Original Research

Published on 09 Oct 2025

Patient and clinician perspectives on pharmacogenetic testing for antipsychotics

in Pharmacogenetics and Pharmacogenomics

Maria Richards-Brown
Yiran Wei
Rosemary Abidoph
Lauren Varney
Marius Cotic
Stephen Murtough
Daniele Panconesi
Daisy Mills
Alvin Richards-Belle
Noushin Saadullah Khani

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1689300

2,508 views

Original Research

Published on 08 Oct 2025

A digital twin of glimepiride for personalized and stratified diabetes treatment

in Pharmacogenetics and Pharmacogenomics

Michelle Elias
Matthias König

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1686415

1,697 views

Original Research

Published on 02 Oct 2025

Genetic and serum biomarkers of NSAID hypersensitivity reactions

in Pharmacogenetics and Pharmacogenomics

G. Amo
J. M. García-Menaya
M. Martí
J. Gómez-Tabales
J. A. Cornejo-García
N. Blanca-López
G. Canto
I. Doña
M. Blanca
M. J. Torres

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1502755

2,294 views

Review

Published on 01 Oct 2025

Pharmacogenomics of antibiotic-induced hypersensitivity reactions: current evidence and implications in clinical practice

in Pharmacogenetics and Pharmacogenomics

Mohitosh Biswas
Murshadul Alam Murad
Md. Ismail Hossain Ashik
Maliheh Ershadian
Chonlaphat Sukasem

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1651909

2,913 views
1 citation

Original Research

Published on 25 Sep 2025

Pharmacogenomic biomarkers of ACE inhibitor–induced cough in a multi-ethnic UAE cohort

in Pharmacogenetics and Pharmacogenomics

Sahar M. Altoum
Zeina N. Al-Mahayri
Lubna Q. Khasawneh
Mais N. Alqasrawi
Lilas Dabaghie
Dana Hamza
Bassam R. Ali

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1655617

2,246 views

Systematic Review

Published on 22 Sep 2025

Implementing pharmacogenetic testing in community pharmacy practice: a scoping review

in Pharmacogenetics and Pharmacogenomics

Aude Coumau
Claire Coumau
Chantal Csajka

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1659875

3,681 views

Review

Published on 19 Sep 2025

Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions

in Pharmacogenetics and Pharmacogenomics

Hamid A. Alhaj
Jana Samara
Alyamama Alnamous
Rama Karima
Maha Saber-Ayad

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1651898

4,112 views
1 citation

Original Research

Published on 19 Sep 2025

Prevalence of risk phenotypes associated with CYP2C92, 3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice

in Pharmacogenetics and Pharmacogenomics

Mohitosh Biswas
Murshadul Alam Murad
Maliheh Ershadian
Most. Sumaiya Khatun Kali
Maw Shin Sim
Baharudin Ibrahim
Chonlaphat Sukasem

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1597379

1,935 views
1 citation

Original Research

Published on 18 Sep 2025

Higher prevalence of NUDT15 rs116855232 compared to TPMT rs1142345 in a Chinese cohort and its implications for thiopurine therapy

in Pharmacogenetics and Pharmacogenomics

Chenyu Zhao
Hui Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1660719

1,634 views

Original Research

Published on 18 Sep 2025

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

in Pharmacogenetics and Pharmacogenomics

Rocío Rosas-Alonso
Nuria Rodríguez Salas
Pablo Perez Wert
Angela Hoyo
Susana Martin-López
Daniel Martínez-Pérez
Iciar Ruiz-Gutiérrez
Diego Jiménez-Bou
Jesús Peña
Pedro Arias

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1645188

2,072 views

Brief Research Report

Published on 09 Sep 2025

Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling

in Pharmacogenetics and Pharmacogenomics

Koen Deserranno
Laurentijn Tilleman
Dieter Deforce
Filip Van Nieuwerburgh

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1653999

2,810 views

Review

Published on 04 Sep 2025

Epigenetics in pharmacogenes encoding metabolizing enzymes of second-generation antipsychotics used in schizophrenia and its clinical implications

in Pharmacogenetics and Pharmacogenomics

Angel T. Alvarado
Amparo Iris Zavaleta
César Li-Amenero
María R. Bendezú
Jorge A. Garcia
Haydee Chávez
Juan J. Palomino-Jhong
Felipe Surco-Laos
Doris Laos-Anchante
Elizabeth J. Melgar-Merino

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1611203

3,044 views
1 citation

Original Research

Published on 01 Sep 2025

The prevalence of genetic variants of the Mas-related G-protein-coupled receptor X2 in patients does not explain perioperative hypersensitivity reactions to neuromuscular blocking agents

in Pharmacogenetics and Pharmacogenomics

Alicja Dziadowiec
Mateusz Kwitniewski
Peter Kopac
Hubert Rybka
Lenka Sedlackova
Adriana Srotova
Wojciech Dyga
Ana Koren
Joanna Gluck
Radoslaw Kitel

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1655722

2,167 views

639 articles

articles

Transcriptional rewiring in cancer driven by POLR2A/RPB1: mechanistic insights, non-coding RNA crosstalk, and therapeutic opportunities

Combining Exercise and Nanoparticle-Based Therapies: A Review of Physiological Synergies and Pharmacological Potential

StarTRAC-CYP2D6: a method for CYP2D6 allele-specific copy number determination using digital PCR

Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis

Pharmacogenetic variations and clinical implications of actionable CYP2D6/CYP2C19 variants in Central Indian patients with common mental disorders

Assessing the views and opinions of psychiatric patients receiving genome-guided treatment within the scope of the PREPARE preemptive pharmacogenomics clinical study

Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis

Pharmacogenetic associations of CYP2D6 and CYP2C19 variants with anticholinergic drug burden and hyposalivation

Inhibition of mesenchymal drift as a strategy for rejuvenation

Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder

Epigenetic pharmacology in aging: from mechanisms to therapies for age-related disorders

Patient and clinician perspectives on pharmacogenetic testing for antipsychotics

A digital twin of glimepiride for personalized and stratified diabetes treatment

Genetic and serum biomarkers of NSAID hypersensitivity reactions

Pharmacogenomics of antibiotic-induced hypersensitivity reactions: current evidence and implications in clinical practice

Pharmacogenomic biomarkers of ACE inhibitor–induced cough in a multi-ethnic UAE cohort

Implementing pharmacogenetic testing in community pharmacy practice: a scoping review

Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions

Prevalence of risk phenotypes associated with CYP2C92, 3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice

Higher prevalence of NUDT15 rs116855232 compared to TPMT rs1142345 in a Chinese cohort and its implications for thiopurine therapy

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling

Epigenetics in pharmacogenes encoding metabolizing enzymes of second-generation antipsychotics used in schizophrenia and its clinical implications

The prevalence of genetic variants of the Mas-related G-protein-coupled receptor X2 in patients does not explain perioperative hypersensitivity reactions to neuromuscular blocking agents

articles

Transcriptional rewiring in cancer driven by POLR2A/RPB1: mechanistic insights, non-coding RNA crosstalk, and therapeutic opportunities

Combining Exercise and Nanoparticle-Based Therapies: A Review of Physiological Synergies and Pharmacological Potential

StarTRAC-CYP2D6: a method for CYP2D6 allele-specific copy number determination using digital PCR

Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis

Pharmacogenetic variations and clinical implications of actionable CYP2D6/CYP2C19 variants in Central Indian patients with common mental disorders

Assessing the views and opinions of psychiatric patients receiving genome-guided treatment within the scope of the PREPARE preemptive pharmacogenomics clinical study

Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis

Pharmacogenetic associations of CYP2D6 and CYP2C19 variants with anticholinergic drug burden and hyposalivation

Inhibition of mesenchymal drift as a strategy for rejuvenation

Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder

Epigenetic pharmacology in aging: from mechanisms to therapies for age-related disorders

Patient and clinician perspectives on pharmacogenetic testing for antipsychotics

A digital twin of glimepiride for personalized and stratified diabetes treatment

Genetic and serum biomarkers of NSAID hypersensitivity reactions

Pharmacogenomics of antibiotic-induced hypersensitivity reactions: current evidence and implications in clinical practice

Pharmacogenomic biomarkers of ACE inhibitor–induced cough in a multi-ethnic UAE cohort

Implementing pharmacogenetic testing in community pharmacy practice: a scoping review

Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions

Prevalence of risk phenotypes associated with CYP2C9*2, *3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice

Higher prevalence of NUDT15 rs116855232 compared to TPMT rs1142345 in a Chinese cohort and its implications for thiopurine therapy

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling

Epigenetics in pharmacogenes encoding metabolizing enzymes of second-generation antipsychotics used in schizophrenia and its clinical implications

The prevalence of genetic variants of the Mas-related G-protein-coupled receptor X2 in patients does not explain perioperative hypersensitivity reactions to neuromuscular blocking agents

Prevalence of risk phenotypes associated with CYP2C92, 3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice